Partnerships

Partnering

Our partnering approach incorporates creative methodologies that ensure the business goals of both parties are met. Our partnerships can take many forms:

  • In-license/acquire branded pediatric prescription products
  • Out-license technology-based NDA products worldwide
  • Co-develop partner molecules that benefit from our technologies
  • In-license/acquire and/or co-develop ANDA products

For more information, please contact our business development team at Development@trispharma.com.


Partners

Our strategic partnerships range from co-development to licensing and royalty arrangements with a wide range of organizations.

pfizer.jpg#asset:347
vernalis.jpg#asset:349
breckenridge.jpg#asset:350
teva.jpg#asset:351
perrigo.jpg#asset:352

Partner Updates

FDA accepts CCP-08 NDA for full review

PDUFA date of 4 August 2017

FDA accepts CCP-07 NDA for full review

PDUFA date of 20 April 2017

Pfizer Receives U.S. FDA Approval of New QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets CII

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above

See more...